Published in Lab Business Week, December 25th, 2005
"Monotherapy with interferon (IFN) or lamivudine is effective in a limited proportion of CHB patients. A sequential combination may have better therapeutic effects by sustained viral suppression combined with immunomodulation," wrote S.K. Sarin and colleagues, University of Delhi.
"To compare the efficacy of sequential lamivudine and IFN therapy versus lamivudine monotherapy in HBeAg positive CHB patients, 75 treatment naive HBeAg positive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.